Abstract | AIM: METHODS: A phase IV, prospective, open-label, uncontrolled exploratory study including subjects with subfoveal NV-AMD who had had one to three induction treatments 30-120 days before entry and showed investigator-determined clinical/anatomical NV-AMD improvement. Lesions in the study eye were: any subtype, 12 or fewer disc areas; postinduction centre point thickness ( CPT) 275 μm or less or thinning of 100 μm or more (optical coherence tomography); visual acuity (VA) 20/20-20/400. Intravitreal pegaptanib 0.3 mg was administered as maintenance every 6 weeks for 48 weeks with follow-up to week 54. Booster treatment additional unscheduled treatment for wet age-related macular degeneration, was allowed in the study eye at the investigators' discretion for clinical deterioration. RESULTS: Of 568 enrolled subjects, 86% completed 1 year of pegaptanib. Mean VA improvement during induction (49.6 to 65.5 letters) was well preserved (54-week mean 61.8 letters). Mean CPT was relatively stable during maintenance (20 μm increase during the study). Fifty per cent did not receive unscheduled booster treatment to week 54; 46% did have one such booster (mean 147 days after maintenance initiation). CONCLUSIONS: An induction-maintenance strategy, using non-selective then selective vascular endothelial growth factor ( VEGF) inhibitors, could be considered for NV-AMD. This approach may have particular relevance for patients with systemic comorbidities who require long-term anti- VEGF therapy for NV-AMD.
|
Authors | Thomas R Friberg, Michael Tolentino, LEVEL Study Group, Pamela Weber, Sunil Patel, Scott Campbell, Mauro Goldbaum |
Journal | The British journal of ophthalmology
(Br J Ophthalmol)
Vol. 94
Issue 12
Pg. 1611-7
(Dec 2010)
ISSN: 1468-2079 [Electronic] England |
PMID | 20472746
(Publication Type: Clinical Trial, Phase IV, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Aptamers, Nucleotide
- Vascular Endothelial Growth Factor A
- pegaptanib
|
Topics |
- Aged
- Angiogenesis Inhibitors
(therapeutic use)
- Aptamers, Nucleotide
(therapeutic use)
- Cornea
(blood supply)
- Female
- Humans
- Macular Degeneration
(drug therapy, physiopathology)
- Male
- Middle Aged
- Prospective Studies
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(physiology)
- Wet Macular Degeneration
(drug therapy, physiopathology)
|